What is Selpercatinib?

Selpercatinib is a kinase inhibitor with higher specificity for RET tyrosine kinase receptors (RTKs) than other RTKs. Enhanced RET (rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors have been shown to be effective against RET-driven cancers, their lack of specificity is often associated with substantial toxicity. Serpatinib is a first-generation specific RET RTK inhibitor for the treatment of RET-driven cancers.

Serpatinib for RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid carcinoma (MTC), RET fusion-positive thyroid cancer, and Treatment of adult patients with locally advanced or metastatic solid tumors with RET gene fusion. These patients have received other drug treatments before treatment with this drug, such as immunotherapy and/or platinum-based chemotherapy, radioactive iodine, etc. RET gene fusion and RET gene mutation testing should be performed before starting the drug.

The original drug Serpatinib has not yet been launched in China, so it is not covered by medical insurance. Domestic patients cannot yet purchase this drug. Serpatinib marketed overseas The original drug has a US version and a European version. The price of the US version is about 150,000 yuan per box of 80mg*60 pills. The price of the European version of 80mg*56 pills per box is about 21,000 yuan (the price may fluctuate due to the exchange rate), which is expensive. There are also serpatinibgeneric drugs produced abroad. The specification produced by a Bangladesh pharmaceutical factory is 40mg*30 pills per box and the price is about 4,300 yuan (the price may fluctuate due to the exchange rate). The ingredients of the generic drugs are basically the same as those of the original drug.